TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors.
Expert Opin Investig Drugs
; 29(8): 869-880, 2020 Aug.
Article
in En
| MEDLINE
| ID: mdl-32551999
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Leukemia, Lymphocytic, Chronic, B-Cell
/
Tumor Suppressor Protein p53
/
Antineoplastic Agents
Type of study:
Guideline
Limits:
Humans
Language:
En
Journal:
Expert Opin Investig Drugs
Journal subject:
TERAPIA POR MEDICAMENTOS
Year:
2020
Document type:
Article
Affiliation country:
Israel
Country of publication:
Reino Unido